Oxford Brookes University Bsc. (Hons.) in Applied Accounting

 Research Presentation

“The financial and business performance of Pfizer from 1 January 2012 to 31 December 2014”

Name:

Contents

1. Research topic and reasons

2. Aims of the research

3. Objectives of the research

4. Research questions

5. Research approach

6. Analysis

7. Conclusion and recommendations

Topic chosen

“The financial and business performance analysis of

Pfizer from 1 January 2012 to 31 December 2014”

Reasons• Possess necessary skills

• Have interest in the area

• Opportunity to practice the skills

• Availability of secondary data

Research aims

Analyse the business and financial performance of

Pfizer from January 2012 to December 2014

Objectives of the research

1. Find out what factors impact on the performance of companies in the pharmaceutical industry.

2. Find out the opportunities and threats that Pfizer faces.3. Find out the factors that contribute to Pfizer’s strengths

and weaknesses.4. Find out how Pfizer has performed financially during

the three-year period from January 2012 to December 2014.

5. Give suggestions on what Pfizer should do to improve its business and financial performance.

Research questions

1. What are the general business factors that affect the pharmaceutical industry?

2. What are the threats and opportunities present in the general environment?

3. What are Pfizer’s strengths and weaknesses?4. What has been Pfizer’s financial performance during

the three-year period from January 2012 to December 2014?

5. What should Pfizer do to improve its performance?

RESEARCH APPROACH 

1. PESTEL

2. SWOT

3. Ratio analysis

4. Conclusions

PESTEL

1. Political stability and security

2. Government policies on health care systems

3. Economic growth

4. Taxation

5. Currency exchange rates

6. Demographics

7. Lifestyle choices

PESTEL (continued)

1. Research and development

2. Sustainable development

3. Patent rights

4. Price fixing

5. Personal lawsuits

6. Laws and regulations

7. Unethical clinic trials

SWOT

SWOT

2014 2013 2012 2014 2013 2012GlaxoSmithkline Pfizer

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

-

0.1

0.2

0.3

0.4

0.5

0.6

0.7

Profitability Ratios

Tim

es

2014 2013 2012 2014 2013 2012GlaxoSmithkline Pfizer

-

50

100

150

200

250

300

350

400

450

-

0.5

1.0

1.5

2.0

2.5

3.0

Liquidity Ratios

Days Tim

es

2014 2013 2012 2014 2013 2012GlaxoSmithkline Pfizer

0%

50%

100%

150%

200%

250%

300%

350%

400%

-

2.0

4.0

6.0

8.0

10.0

12.0

Risk Ratios

Tim

es

2013 2012 2011Pfizer

-

0.50

1.00

1.50

2.00

2.50

3.00

3.50

Pfizer Shareholders Ratios

$

Conclusion

1. Mixed financial performance

2. Decline in profitability

3. Good working capital management

4. Low risk levels

5. Improving shareholder value

6. Opportunity to venture into new markets

7. Speed up research and development of products

8. Tackle counterfeit products